Blue Owl Capital and Canada Pension Plan Investment Board have stepped in to bulk up cash reserves at BridgeBio as it prepares for the launch of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) and a market showdown with much larger rival Pfizer and its $2.5 billion Vyndaqel/Vyndamax (tafamidis) franchise, plus an extensive late-stage clinical trials programme.
The financing includes $300 million from Blue Owl and $200 million from CPPIB Credit that will be payable on the first approval of acoramidis and help fund its rollout, in return for royalties of 5% of worldwide net sales.
